Vitiligo- and Melanoma-associated Hypopigmentation: a Similar Appearance but a Different Mechanism

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1994 Jun 1

PMID 8205563

Citations 6

Authors

O Merimsky

Y Shoenfeld

G Yecheskel

S Chaitchik

E Azizi

P Fishman

Affiliations

Soon will be listed here.

Abstract

The significance of the association between the appearance of hypopigmentation in patients with melanoma and the prognosis is still not clear. It was postulated that, in melanoma, an immune response is responsible for the destruction of the malignant as well as the normal pigmented cells, and that the eventual development of vitiligo-like patches in melanoma patients improves their prognosis. We studied the level of anti-melanoma antibodies in the sera of patients with melanoma with hypopigmentation and compared it to the titer in patients with melanoma only, to the titer of patients with vitiligo, and to that of healthy subjects. Only IgG-type antibodies were found in the sera of patients with vitiligo, with melanoma, or with melanoma with hypopigmentation. No significant differences in the titer of anti-melanoma antibodies could be found between the patients with melanoma when subgrouped according to the initial stage and the status of the disease at the time when the test was carried out. Statistically significantly (P < 0.001) higher titers of antibodies were detected in the sera of patients with vitiligo in comparison to the lower titers in the other groups. Our results point to a similar immunobiological status, which probably does not give any advantage to patients with melanoma with hypopigmentation compared to patients without it. The appearance of hypopigmentary plaques in melanoma patients should be regarded, in our opinion, as a concomitant immunological phenomenon of the disease.

Citing Articles

Vitiligo-Thyroid Disease Association: When, in Whom, and Why Should It Be Suspected? A Systematic Review.

Chivu A, Balasescu E, Pandia L, Nedelcu R, Brinzea A, Turcu G J Pers Med. 2022; 12(12).

PMID: 36556267 PMC: 9785784. DOI: 10.3390/jpm12122048.

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma.

Wang C, Li M, Wei R, Wu J J Bone Oncol. 2020; 25:100332.

PMID: 33145154 PMC: 7591383. DOI: 10.1016/j.jbo.2020.100332.

New perspectives on the role of vitiligo in immune responses to melanoma.

Byrne K, Turk M Oncotarget. 2011; 2(9):684-94.

PMID: 21911918 PMC: 3248219. DOI: 10.18632/oncotarget.323.

Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin.

Cho E, Lee M, Kang H, Lee S, Kim H, Park Y Ann Dermatol. 2010; 21(2):178-81.

PMID: 20523781 PMC: 2861199. DOI: 10.5021/ad.2009.21.2.178.

The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions.

Merimsky O, Shoenfeld Y, Fishman P Clin Rev Allergy Immunol. 1998; 16(3):227-36.

PMID: 9773250 DOI: 10.1007/BF02737633.

References

Dunston G, Halder R . Vitiligo is associated with HLA-DR4 in black patients. A preliminary report. Arch Dermatol. 1990; 126(1):56-60. View

Morton D, Foshag L, Hoon D, Nizze J, Famatiga E, Wanek L . Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992; 216(4):463-82. PMC: 1242654. DOI: 10.1097/00000658-199210000-00010. View

HORNUNG M, Krementz E . Specific tissue and tumor responses of chimpanzees following immunization against human melanoma. Surgery. 1974; 75(4):477-86. View

DONALDSON R, CANAAN Jr S, McLEAN R, ACKERMAN L . Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery. 1974; 76(5):771-8. View

Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P . Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993; 177(4):989-98. PMC: 2190978. DOI: 10.1084/jem.177.4.989. View

McBurney E . Vitiligo. Clinical picture and pathogenesis. Arch Intern Med. 1979; 139(11):1295-7. DOI: 10.1001/archinte.139.11.1295. View

Soubiran P, Benzaken S, Bellet C, Lacour J, Ortonne J . Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies. Br J Dermatol. 1985; 113 Suppl 28:124-7. DOI: 10.1111/j.1365-2133.1985.tb15640.x. View

Galbraith G, Miller D, Emerson D . Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. Clin Immunol Immunopathol. 1988; 48(3):317-24. DOI: 10.1016/0090-1229(88)90025-6. View

Harning R, Cui J, Bystryn J . Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991; 97(6):1078-80. DOI: 10.1111/1523-1747.ep12492607. View

10.

Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Ferrone S . Vitiligo autoantibodies are effective against melanoma. Cancer. 1993; 72(8):2365-9. DOI: 10.1002/1097-0142(19931015)72:8<2365::aid-cncr2820720812>3.0.co;2-g. View

11.

Nordlund J, Kirkwood J, Forget B, MILTON G, Albert D, LERNER A . Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983; 9(5):689-96. DOI: 10.1016/s0190-9622(83)70182-9. View

12.

Hertz K, Gazze L, Kirkpatrick C, Katz S . Autoimmune vitiligo: detection of antibodies to melanin-producing cells. N Engl J Med. 1977; 297(12):634-7. DOI: 10.1056/NEJM197709222971204. View

13.

Naughton G, Reggiardo D, Bystryn J . Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol. 1986; 15(5 Pt 1):978-81. DOI: 10.1016/s0190-9622(86)70260-0. View

14.

Lewis M, Phillips T, Cook K, Blake J . Possible explanation for loss of detectable antibody in patients with disseminated malignant melanoma. Nature. 1971; 232(5305):52-4. DOI: 10.1038/232052a0. View

15.

Brostoff J . Autoantibodies in patients with vitiligo. Lancet. 1969; 2(7613):177-8. DOI: 10.1016/s0140-6736(69)91421-4. View

16.

LERNER A, CAGE G . Melanomas in horses. Yale J Biol Med. 1973; 46(5):646-9. PMC: 2592037. View

17.

Hom S, Topalian S, Simonis T, Mancini M, Rosenberg S . Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother (1991). 1991; 10(3):153-64. View

18.

Bystryn J . Serum antibodies in vitiligo patients. Clin Dermatol. 1989; 7(2):136-45. DOI: 10.1016/0738-081x(89)90063-1. View

19.

Betterle C, Del Prete G, Peserico A, Bersani G, Caracciolo F, Trisotto A . Autoantibodies in vitiligo. Arch Dermatol. 1976; 112(9):1328. View

20.

Old L, STOCKERT E, Boyse E, Kim J . Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med. 1968; 127(3):523-39. PMC: 2138467. DOI: 10.1084/jem.127.3.523. View